Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
- D3.196 - Efficacy of sublingual immunotherapy in children with allergic rhinitis
D3.193 - Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study
D3.194 - Renewal’s analysis of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: SPEED study, a Real-Life study
D3.195 - Reasons for declining venom immunotherapy and its burden on patients' daily lives
D3.197 - When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus
D3.198 - Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy
D3.202 - Allergen-Specific Immunotherapy Is Still Rarely Used: Results of an Online Survey in Lithuania
D3.203 - Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts
D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment
D3.205 - Online Education Increases Clinician Knowledge and Confidence in Utilizing Allergen Immunotherapy for Respiratory Allergic Disease
- D3.100 - Risk Factors and Biomarkers for COVID-19 and Allergic Diseases
- D3.102 - PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience
- D3.103 - Impact of aspirin-induced bronchospasm on the in vitro Aspirin Hypersensitivity Diagnostic Index in the patients with Aspirin Exacerbated Respiratory Disease
- D3.104 - A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study
- D3.105 - Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report
- D3.106 - Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry
- D3.108 - PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma
D3.109 - Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis
- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs
- D3.111 - Lymphocyte profile and asthma control during the treatment with benralizumab in real life
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download